REGULATORY
Chuikyo Snubs Industry’s Call to Exclude Listed Products from CEA Scope
Pharma industry associations of Japan, the US, and Europe were invited to give their views on an envisioned Japanese version of a cost-effective assessment (CEA) scheme on December 19, with a key policy panel member giving a cold shoulder to…
To read the full story
Related Article
REGULATORY
- Lilly’s Oral GLP-1 Obesity Drug Heads to Dec. 2 Panel Review, Eyes Japan First
November 19, 2026
- First Pralia Biosimilars Inching Closer to Japan Approval, 5 Products Lined Up
November 19, 2026
- MHLW Drug Supply Monitoring System Hit by Cyberattack, Possible Data Leak
November 19, 2026
- Expert Calls for Remote MRI Reviews to Monitor Alzheimer’s Drug Risks
November 18, 2026
- Japan Implements ICH Bioequivalence Guideline for Immediate-Release Oral Drugs
November 18, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





